News | August 28, 2012

ICUS Pleased by FDA Modification of Boxed Warnings on Additional Ultrasound Contrast Agents

August 28, 2012 — The International Contrast Ultrasound Society (ICUS) applauded the U.S. Food and Drug Administration’s (FDA) decision to modify the U.S. product label for Optison, an ultrasound contrast agent used to improve the accuracy of radiation-free ultrasound scans. Optison is marketed by GE Healthcare.

The label change was supported by a citizen petition filed by ICUS in October, citing newer scientific studies showing the superior safety profile of ultrasound contrast agents along with their favorable risk-benefit ratios. The citizen petition, which was granted in part by the FDA, also supported a prior modification of the label for Definity, an ultrasound contrast agent marketed by Lantheus Medical Imaging.

The FDA's actions are "an important step forward for patients and for our healthcare system," said Steven Feinstein, a cardiologist at Rush University Medical Center in Chicago and ICUS co-president.

Ultrasound contrast agents are administered intravenously during a noninvasive ultrasound scan to improve image clarity. The procedure does not expose patients to ionizing radiation, and ultrasound contrast agents do not contain dye or increase a patient's risk of nephrotoxicity, according to Feinstein.

"Ultrasound contrast agents are exceedingly safe and completely radiation-free diagnostic imaging tools," he said. "By improving the reliability of a simple front-line ultrasound scan, ultrasound contrast agents also may reduce the need for redundant, expensive and potentially riskier downstream testing — thereby improving patient care while also reducing the overall cost of diagnostic imaging."

The FDA's decision also will spare many patients from the cumulative effects of ionizing radiation that are inherent in certain alternative forms of diagnostic imaging, including SPECT (single photon emission computed tomography) and CT (computed tomography), according to Michael Main, cardiologist and director of the echocardiography laboratory at St. Luke’s Mid-America Heart Institute in Kansas City, Mo., and ICUS treasurer. "The FDA decision should lead to increased use of contrast, better imaging studies, better diagnosis for patients and saved lives," he said.

Main said that although the FDA retained boxed warnings on both ultrasound contrast agents, newer safety data demonstrate a more favorable risk-benefit profile that ultimately may warrant additional label changes with removal of the boxed warnings.

For more information: www.icus-society.org

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
New Vascular Ultrasound Registry Looks to Enhance Patient Care
News | Cardiovascular Ultrasound | January 17, 2018
The Society for Vascular Ultrasound (SVU), the Society for Vascular Surgery (SVS) and Medstreaming-M2S announced the...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Sponsored Content | Videos | Ultrasound Imaging | January 11, 2018
Mindray recently featured a new upgrade for its premium Resona 7 ultrasound system at the Radiological Society of North...
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
New International Report Provides Comprehensive Guide to Imaging in Chagas Heart Disease
News | Cardiovascular Ultrasound | January 03, 2018
Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a...
Bay Labs Completes $5.5 Million Series A Financing for AI-Driven Ultrasound
News | Cardiovascular Ultrasound | December 21, 2017
December 21, 2017 — Bay Labs, a medical technology company applying...
Toshiba Medical Introduces New Entry-Level Aplio i600 Ultrasound Platform
News | Ultrasound Imaging | December 21, 2017
Toshiba Medical, a Canon Group company, showcased the Aplio i600, the newest addition to the premium Aplio i-series...
Overlay Init